Biogen Spinraza Approval: The Perfect Antidote To Sarepta Headlines?
Executive Summary
Approval of Biogen/Ionis’ Spinraza gives the drug development community a successful, collaborative model for a rapid pathway to full approval for a rare disease therapy; it also provides a timely, compelling rebuttal to claims that US FDA’s drug review operations are in dire need of reform.
You may also be interested in...
Biogen's Experience Highlights Challenges With Expanded Access Programs
Expanded access program for rare pediatric disease treatment did not enroll many patients due to clinician community overwhelmed by patient demand and questions over who would pay ancillary drug costs.
BioMarin's Brineura Approval Shows FDA's Open Door For Orphan Drugs
Filing supporting Brineura was supported by a tiny, single-arm study and had no advisory committee review, the latest sign of the US regulatory agency's willingness to speed orphan drugs for serious pediatric diseases.
SMA Patient Meeting Showcases FDA Flexibility – And Appreciation From Advocates
US agency's top neurology review officials received warm reception during Patient Focused Drug Development meeting for Spinal Muscular Atrophy. They also delivered a strong message of continued engagement beyond the first drug approval.